BIEL becomes the story stock for 2026 @ PPS = .003 and the GOAT @ PPS =. 10!
A move to .003 represents a 3,000% gain from .0001 — outperforming the 10-year ROI for Apple, Amazon, Netflix, Microsoft, Google, etc.
When this breakout hits, BIEL/Electrome will receive millions of dollars in free publicity, igniting global awareness and accelerating sales and big money will be chasing the stock
BIEL = GOAT @ PPS = .10!
BIEL hitting PPS .10 puts it in the conversation for the greatest stock ever - more than 100,000% appreciation from their all-time low.
Two companies currently compete for the absolute top spot in modern history: Apple and former penny stock Monster Beverage, with each taking about 30 years to get there. Netflix, Nvidia, Microsoft and Amazon only make the honorable mention list.
$250K IS THE MAGIC NUMBER!
$250,000 profit will get the PPS to COPPER @ P/E = 1,000 (not unusual for stocks turning profitable for the first time and with increasing future growth/revenue/profit projections). This will happen when investors become confident the profit will be achieved - likely long before financials are reported (depending on news). Each additional $250K profit increment should equal an additional .01 PPS:
$250K profit = .01 PPS
$1M profit = .04 PPS
$2M profit = .08 PPS
$2.5M profit = .10 PPS in a year or two makes it the greatest stock in history!
The $500K (2025) revenue base and the $41M tax-loss carryforward accelerates profitability.
Pathway to the PPS Milestones is Highly Compressed
The recent validation from the June 30, 2026, Chairman’s Update confirms that the strategic distribution partnership with Electrome Corporation has officially moved forward, satisfying initial conditions and executing the first purchase orders.
Combined with the company reporting a "small profit for calendar year 2025," aggressive cost reduction (office relocation and staff downsizing), the breakout that will occur @ PPS .003 and a $41M tax-loss carryforward, the financial pathway to the PPS milestones is highly compressed.
Timeline for how BIEL could scale to meet these profit milestones based on the Electrome commercial rollout.
The BIEL / Electrome Milestone Timeline
Phase 1: The Magic Number ($250K Profit) = $0.01 PPS
Target Window: Q3 – Q4 2026
Catalyst: Electrome’s official commercial launch and fulfillment of initial purchase orders.
Investor Psychology: As noted, investors will price this in before the 10-K or 10-Q reports. When Electrome provides public metrics or press releases regarding early consumer adoption and platform integration, speculative volume will flood the ~24.7B shares outstanding.
The Math: Achieving $250K in profit requires very minimal revenue overhead now that BIEL is a lean, 4-employee operation with strict cost controls. A P/E of 1,000 on $250K net income supports a market cap of $250M, lifting the current fraction-of-a-cent price ($0.0003) straight into "copper" ($0.01).
Phase 2: Scaling Up ($1M Profit) = $0.04 PPS
Target Window: H1 2027
Catalyst: Consistent, re-occurring purchase orders from Electrome alongside existing channels (Taiwan, veterinary, etc.).
The Acceleration: The $41M tax-loss carryforward acts as a shield, ensuring that every dollar of operational revenue over expenses goes straight to the bottom line without federal tax erosion. Reaching $1M in profit requires roughly $2M–$2.5M in gross revenue, which is well within reach as Electrome scales manufacturing.
Phase 3: The Inflection Point ($2M Profit) $0.08 PPS
Target Window: Late 2027
Catalyst: Expanded clinical adoption of Pulsed Shortwave Therapy (PSWT) in surgical/postoperative settings and international distribution traction.
Market Dynamics: At $2M in pure profit, BIEL transitions from an OTC micro-cap story into a fundamentally sound, high-growth medical device play.
Phase 4: History in the Making ($2.5M Profit) = $0.10 PPS
Target Window: Mid-2028 (Within the "year or two" window)
Catalyst: Total market penetration via Electrome's commercial platform and mature multi-channel revenue.
The Result: A $0.10 PPS translates to a market capitalization of roughly $2.47 Billion. With zero tax liabilities on the horizon due to the carryforward, an explosive margins profile makes this milestone entirely achievable if Electrome can effectively capture a slice of the multi-billion-dollar non-opioid chronic pain market.
A move to .003 represents a 3,000% gain from .0001 — outperforming the 10-year ROI for Apple, Amazon, Netflix, Microsoft, Google, etc.
When this breakout hits, BIEL/Electrome will receive millions of dollars in free publicity, igniting global awareness and accelerating sales and big money will be chasing the stock
BIEL = GOAT @ PPS = .10!
BIEL hitting PPS .10 puts it in the conversation for the greatest stock ever - more than 100,000% appreciation from their all-time low.
Two companies currently compete for the absolute top spot in modern history: Apple and former penny stock Monster Beverage, with each taking about 30 years to get there. Netflix, Nvidia, Microsoft and Amazon only make the honorable mention list.
$250K IS THE MAGIC NUMBER!
$250,000 profit will get the PPS to COPPER @ P/E = 1,000 (not unusual for stocks turning profitable for the first time and with increasing future growth/revenue/profit projections). This will happen when investors become confident the profit will be achieved - likely long before financials are reported (depending on news). Each additional $250K profit increment should equal an additional .01 PPS:
$250K profit = .01 PPS
$1M profit = .04 PPS
$2M profit = .08 PPS
$2.5M profit = .10 PPS in a year or two makes it the greatest stock in history!
The $500K (2025) revenue base and the $41M tax-loss carryforward accelerates profitability.
Pathway to the PPS Milestones is Highly Compressed
The recent validation from the June 30, 2026, Chairman’s Update confirms that the strategic distribution partnership with Electrome Corporation has officially moved forward, satisfying initial conditions and executing the first purchase orders.
Combined with the company reporting a "small profit for calendar year 2025," aggressive cost reduction (office relocation and staff downsizing), the breakout that will occur @ PPS .003 and a $41M tax-loss carryforward, the financial pathway to the PPS milestones is highly compressed.
Timeline for how BIEL could scale to meet these profit milestones based on the Electrome commercial rollout.
The BIEL / Electrome Milestone Timeline
Phase 1: The Magic Number ($250K Profit) = $0.01 PPS
Target Window: Q3 – Q4 2026
Catalyst: Electrome’s official commercial launch and fulfillment of initial purchase orders.
Investor Psychology: As noted, investors will price this in before the 10-K or 10-Q reports. When Electrome provides public metrics or press releases regarding early consumer adoption and platform integration, speculative volume will flood the ~24.7B shares outstanding.
The Math: Achieving $250K in profit requires very minimal revenue overhead now that BIEL is a lean, 4-employee operation with strict cost controls. A P/E of 1,000 on $250K net income supports a market cap of $250M, lifting the current fraction-of-a-cent price ($0.0003) straight into "copper" ($0.01).
Phase 2: Scaling Up ($1M Profit) = $0.04 PPS
Target Window: H1 2027
Catalyst: Consistent, re-occurring purchase orders from Electrome alongside existing channels (Taiwan, veterinary, etc.).
The Acceleration: The $41M tax-loss carryforward acts as a shield, ensuring that every dollar of operational revenue over expenses goes straight to the bottom line without federal tax erosion. Reaching $1M in profit requires roughly $2M–$2.5M in gross revenue, which is well within reach as Electrome scales manufacturing.
Phase 3: The Inflection Point ($2M Profit) $0.08 PPS
Target Window: Late 2027
Catalyst: Expanded clinical adoption of Pulsed Shortwave Therapy (PSWT) in surgical/postoperative settings and international distribution traction.
Market Dynamics: At $2M in pure profit, BIEL transitions from an OTC micro-cap story into a fundamentally sound, high-growth medical device play.
Phase 4: History in the Making ($2.5M Profit) = $0.10 PPS
Target Window: Mid-2028 (Within the "year or two" window)
Catalyst: Total market penetration via Electrome's commercial platform and mature multi-channel revenue.
The Result: A $0.10 PPS translates to a market capitalization of roughly $2.47 Billion. With zero tax liabilities on the horizon due to the carryforward, an explosive margins profile makes this milestone entirely achievable if Electrome can effectively capture a slice of the multi-billion-dollar non-opioid chronic pain market.
1
